Contact Information Childrens Hospital Bldg R Office 513-636-4200 Email mizunoti@ucmail.uc.edu Peer Reviewed Publications Wiles J.;Isemann B.;Mizuno T.;Tabangin M.;Ward L.;Akinbi H.;Vinks A. 12-01-2015. Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome: A Pilot Study The Journal of pediatrics, 167 6, 1214-1220.e3Mizuno T.;Emoto C.;Fukuda T.;Hammill A.;Adams D.;Vinks A. 11-15-2017. Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies European Journal of Pharmaceutical Sciences, 109 , S124-S131Kaplan J.M.;Zingarelli B.;Krallman K.;Tang Girdwood S.;Lagory D.;Mizuno T.;Fei L.;Wong H.R.;Vinks A.A. 11-01-2018. Phase 1 safety and pharmacokinetic study on the use of pioglitazone in critically ill patients with Intensive Care Medicine, 44 11, 2006-2008Alloway R.R.;Vinks A.A.;Fukuda T.;Mizuno T.;King E.C.;Zou Y.;Jiang W.;Woodle E.S.;Tremblay S.;Klawitter J.;Klawitter J.;Christians U. 11-01-2017. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A PLoS Medicine, 14 11, Shinsako K.;Mizuno T.;Terada T.;Watanabe J.;Kamba T.;Nakamura E.;Ogawa O.;Inui K.I. 10-01-2010. Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: A case study International Journal of Clinical Oncology, 15 5, 512-514Dong M.;Mizuno T.;Vinks A. 09-01-2017. Opportunities for model-based precision dosing in the treatment of sickle cell anemia Blood Cells, Molecules, and Diseases, 67 , 143-147Togashi Y.;Masago K.;Masuda S.;Mizuno T.;Fukudo M.;Ikemi Y.;Sakamori Y.;Nagai H.;Kim Y.;Katsura T.;Mishima M. 09-01-2012. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung ca Cancer Chemotherapy and Pharmacology, 70 3, 399-405Hahn D.;Fukuda T.;Euteneuer J.C.;Mizuno T.;Vinks A.A.;Sadhasivam S.;Emoto C. 08-01-2020. Influence of MRP3 Genetics and Hepatic Expression Ontogeny for Morphine Disposition in Neonatal and Journal of Clinical Pharmacology, 60 8, 992-998McGann P.T.;Niss O.;Dong M.;Marahatta A.;Howard T.A.;Mizuno T.;Lane A.;Kalfa T.A.;Malik P.;Quinn C.T.;Ware R.E.;Vinks A.A. 08-01-2019. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for y American Journal of Hematology, 94 8, 871-879Mizuno T.;Fukuda T.;Emoto C.;Mobberley-Schuman P.;Hammill A.;Adams D.;Vinks A. 08-01-2017. Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infan Pediatric Blood and Cancer, 64 8, Emoto C.;Fukuda T.;Mizuno T.;Schniedewind B.;Christians U.;Adams D.;Vinks A. 08-01-2016. Characterizing the developmental trajectory of sirolimus clearance in neonates and infants CPT: Pharmacometrics and Systems Pharmacology, 5 8, 411-417Kunimatsu S.;Mizuno T.;Fukudo M.;Katsura T. 08-01-2013. Effect of P-glycoprotein and breast cancer resistance protein inhibition on the pharmacokinetics of Drug Metabolism and Disposition, 41 8, 1592-1597Dong M.;McGann P.;Mizuno T.;Ware R.;Vinks A. 07-01-2018. Model-based dosing with concentration feedback as an integral part of personalized hydroxycarbamide British Journal of Clinical Pharmacology, 84 7, 1410-1412Faircloth J.M.;Miner K.M.;Alsaied T.;Nelson N.;Ciambarella J.;Mizuno T.;Palumbo J.S.;Vinks A.A.;Veldtman G.R. 07-01-2017. Time in therapeutic range as a marker for thrombotic and bleeding outcomes in Fontan patients Journal of Thrombosis and Thrombolysis, 44 1, 38-47Brunet M.;Van Gelder T.;Åsberg A.;Haufroid V.;Hesselink D.;Langman L.;Lemaitre F.;Marquet P.;Seger C.;Shipkova M.;Vinks A.;Wallemacq P.;Wieland E.;Woillard J.;Barten M.;Budde K.;Colom H.;Dieterlen M.;Elens L.;Johnson-Davis K.;Kunicki P.;Macphee I.;Masuda S.;Mathew B.;Millán O.;Mizuno T.;Moes D.;Monchaud C.;Noceti O.;Pawinski T.;Picard N.;Van Schaik R.;Sommerer C.;Vethe N.;De Winter B.;Christians U.;Bergan S. 06-01-2019. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report Therapeutic Drug Monitoring, 41 3, 261-307Mizuno T.;Gist K.M.;Gao Z.;Wempe M.F.;Alten J.;Cooper D.S.;Goldstein S.L.;Vinks A.A. 06-01-2019. Developmental Pharmacokinetics and Age-Appropriate Dosing Design of Milrinone in Neonates and Infant Clinical Pharmacokinetics, 58 6, 793-803Diwan T.;Lichvar A.;Leino A.;Vinks A.;Christians U.;Shields A.;Cardi M.;Fukuda T.;Mizuno T.;Kaiser T.;Woodle E.;Alloway R. 06-01-2017. Pharmacokinetic and pharmacogenetic analysis of immunosuppressive agents after laparoscopic sleeve g Clinical Transplantation, 31 6, Tsuda M.;Terada T.;Mizuno T.;Katsura T.;Shimakura J.;Inui K. 06-01-2009. Targeted disruption of the multidrug and toxin extrusion 1 (Mate1) gene in mice reduces renal secret Molecular Pharmacology, 75 6, 1280-1286van Hoogdalem M.W.;Emoto C.;Fukuda T.;Mizuno T.;Mehta P.A.;Vinks A.A. 05-01-2020. Population pharmacokinetic modelling of busulfan and the influence of body composition in paediatric British Journal of Clinical Pharmacology, 86 5, 933-943Ramsey L.;Mizuno T.;Vinks A.;O'Brien M. 05-01-2019. Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving Pediatric Blood and Cancer, 66 5, Balyan R.;Zhang X.;Chidambaran V.;Martin L.;Mizuno T.;Fukuda T.;Vinks A.;Sadhasivam S. 05-01-2017. OCT1 genetic variants are associated with postoperative morphine-related adverse effects in children Pharmacogenomics, 18 7, 621-629Gist K.;Cooper D.;Wrona J.;Faubel S.;Altmann C.;Gao Z.;Marino B.;Alten J.;Hock K.;Mizuno T.;Vinks A.;Joy M.;Wempe M.;Bennett M.;Goldstein S. 04-01-2018. Acute Kidney Injury Biomarkers Predict an Increase in Serum Milrinone Concentration Earlier Than Ser Therapeutic Drug Monitoring, 40 2, 186-194Dong M.;McGann P.;Mizuno T.;Ware R.;Vinks A. 04-01-2016. Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in British Journal of Clinical Pharmacology, 81 4, 742-752Hahn A.;Fukuda T.;Hahn D.;Mizuno T.;Frenck R.;Vinks A. 04-01-2016. Pharmacokinetics and pharmacogenomics of ?-lactam-induced neutropenia Pharmacogenomics, 17 6, 547-559Mizuno T.;Mohri K.;Nasu S.;Danjo K.;Okamoto H. 03-04-2009. Dual imaging of pulmonary delivery and gene expression of dry powder inhalant by fluorescence and bi Journal of Controlled Release, 134 2, 149-154Hahn D.;Emoto C.;Euteneuer J.;Mizuno T.;Vinks A.;Fukuda T. 03-01-2019. Influence of OCT1 Ontogeny and Genetic Variation on Morphine Disposition in Critically Ill Neonates: Clinical Pharmacology and Therapeutics, 105 3, 761-768Chidambaran V.;Venkatasubramanian R.;Zhang X.;Martin L.;Niu J.;Mizuno T.;Fukuda T.;Meller J.;Vinks A.;Sadhasivam S. 03-01-2017. ABCC3 genetic variants are associated with postoperative morphine-induced respiratory depression and Pharmacogenomics Journal, 17 2, 162-169Ramsey L.;Mizuno T.;Vinks A.;Margolis P. 03-01-2017. Learning Health Systems as Facilitators of Precision Medicine Clinical Pharmacology and Therapeutics, 101 3, 359-367Nehus E.;Mizuno T.;Cox S.;Goldstein S.;Vinks A. 03-01-2016. Pharmacokinetics of meropenem in children receiving continuous renal replacement therapy: Validation Journal of clinical pharmacology, 56 3, 291-297Kodawara T.;Mizuno T.;Taue H.;Hashida T.;Yano I.;Katsura T.;Inui K. 03-01-2009. Evaluation of stability of temozolomide in solutions after opening the capsule Yakugaku Zasshi, 129 3, 353-357Bauman L.E.;Xiong Y.;Mizuno T.;Minar P.;Fukuda T.;Dong M.;Rosen M.J.;Vinks A.A. 02-11-2020. Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Diseases, 26 3, 429-439Mizuno T.;Terada T.;Kamba T.;Fukudo M.;Katsura T.;Nakamura E.;Ogawa O.;Inui K. 02-06-2010. ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcino Annals of Oncology, 21 6, 1382-1383Emoto C.;Hahn D.;Euteneuer J.;Mizuno T.;Vinks A.;Fukuda T. 02-01-2020. Next Challenge From the Variance in Individual Physiologically-Based Pharmacokinetic Model-Predicted Clinical Pharmacology and Therapeutics, 107 2, 319-320Mizuno T.;O'Brien M.;Vinks A. 02-01-2019. Significant effect of infection and food intake on sirolimus pharmacokinetics and exposure in pediat European Journal of Pharmaceutical Sciences, 128 , 209-214Fukudo M.;Ito T.;Mizuno T.;Shinsako K.;Hatano E.;Uemoto S.;Kamba T.;Yamasaki T.;Ogawa O.;Seno H.;Chiba T.;Matsubara K. 02-01-2014. Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepat Clinical Pharmacokinetics, 53 2, 185-196Mizuno T.;Dong M.;Taylor Z.L.;Ramsey L.B.;Vinks A.A. 01-01-2020. Clinical implementation of pharmacogenetics and model-informed precision dosing to improve patient c British Journal of Clinical Pharmacology, , Tang Girdwood S.C.;Mizuno T.;Krallman K.A.;Benken L.A.;Stoneman E.M.;Yunger T.M.;Wong H.R.;Vinks A.A.;Kaplan J.M. 01-01-2020. Route of oseltamivir administration affects metabolite concentrations in critically ill children Pediatric Infectious Disease Journal, , 1224-1227Taylor Z.L.;Mizuno T.;Punt N.C.;Baskaran B.;Navarro Sainz A.;Shuman W.;Felicelli N.;Vinks A.A.;Heldrup J.;Ramsey L.B. 01-01-2020. MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to In Clinical Pharmacology and Therapeutics, , Vinks A.A.;Punt N.C.;Menke F.;Kirkendall E.;Butler D.;Duggan T.J.;Cortezzo D.M.E.;Kiger S.;Dietrich T.;Spencer P.;Keefer R.;Setchell K.D.R.;Zhao J.;Euteneuer J.C.;Mizuno T.;Dufendach K.R. 01-01-2020. Electronic Health Record–Embedded Decision Support Platform for Morphine Precision Dosing in Neonate Clinical Pharmacology and Therapeutics, 107 1, 186-194Boucher A.;Mizuno T.;Vinks A.;Goldstein S.;Tiao G.;Geller J. 01-01-2019. Dose modifications and pharmacokinetics of adjuvant cisplatin monotherapy while on hemodialysis for Pediatric Blood and Cancer, 66 1, Cabrera-Salcedo C.;Mizuno T.;Tyzinski L.;Andrew M.;Vinks A.A.;Frystyk J.;Wasserman H.;Gordon C.M.;Hwa V.;Backeljauw P.;Dauber A. 01-01-2017. Pharmacokinetics of IGF-1 in PAPP-A2-deficient patients, growth response, and effects on glucose and Journal of Clinical Endocrinology and Metabolism, 102 12, 4568-4577Chidambaran V.;Pilipenko V.;Spruance K.;Venkatasubramanian R.;Niu J.;Fukuda T.;Mizuno T.;Zhang K.;Kaufman K.;Vinks A.;Martin L.;Sadhasivam S. 01-01-2017. Fatty acid amide hydrolase-morphine interaction influences ventilatory response to hypercapnia and p Pharmacogenomics, 18 2, 143-156Mizuno T.;Fukuda T.;Christians U.;Perentesis J.;Fouladi M.;Vinks A. 01-01-2017. Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: British Journal of Clinical Pharmacology, 83 5, 1097-1107Emoto C.;Fukuda T.;Mizuno T.;Cox S.;Schniedewind B.;Christians U.;Widemann B.C.;Fisher M.J.;Weiss B.;Perentesis J.;Vinks A.A. 01-01-2015. Age-dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1 Therapeutic Drug Monitoring, 37 3, 395-399Gist K.M.;Mizuno T.;Goldstein S.L.;Vinks A. 01-01-2015. Retrospective evaluation of milrinone pharmacokinetics in children with kidney injury Therapeutic Drug Monitoring, 37 6, 792-796Ishii T.;Hatano E.;Taura K.;Mizuno T.;Kawai T.;Fukudo M.;Katsura T.;Uemoto S. 01-01-2014. Sorafenib in a hepatocellular carcinoma patient with end-stage renal failure: A pharmacokinetic stud Hepatology Research, 44 6, 685-688Mizuno T.;Fukuda T.;Masuda S.;Uemoto S.;Matsubara K.;Inui K.;Vinks A. 01-01-2014. Developmental trajectory of intestinal MDR1/ABCB1 mRNA expression in children British Journal of Clinical Pharmacology, 77 5, 910-912Mizuno T.;Fukudo M.;Fukuda T.;Terada T.;Dong M.;Kamba T.;Yamasaki T.;Ogawa O.;Katsura T.;Inui K.I.;Vinks A.A.;Matsubara K. 01-01-2014. The Effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal Therapeutic Drug Monitoring, 36 3, 310-316Venkatasubramanian R.;Fukuda T.;Niu J.;Mizuno T.;Chidambaran V.;Vinks A.;Sadhasivam S. 01-01-2014. ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children Pharmacogenomics, 15 10, 1297-1309Fukuda T.;Chidambaran V.;Mizuno T.;Venkatasubramanian R.;Ngamprasertwong P.;Olbrecht V.;Esslinger H.;Vinks A.;Sadhasivam S. 01-01-2013. OCT1 genetic variants influence the pharmacokinetics of morphine in children Pharmacogenomics, 14 10, 1141-1151Mizuno T.;Fukudo M.;Terada T.;Kamba T.;Nakamura E.;Ogawa O.;Inui K.I.;Katsura T. 01-01-2012. Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacoki Drug Metabolism and Pharmacokinetics, 27 6, 631-639
Peer Reviewed Publications Wiles J.;Isemann B.;Mizuno T.;Tabangin M.;Ward L.;Akinbi H.;Vinks A. 12-01-2015. Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome: A Pilot Study The Journal of pediatrics, 167 6, 1214-1220.e3Mizuno T.;Emoto C.;Fukuda T.;Hammill A.;Adams D.;Vinks A. 11-15-2017. Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies European Journal of Pharmaceutical Sciences, 109 , S124-S131Kaplan J.M.;Zingarelli B.;Krallman K.;Tang Girdwood S.;Lagory D.;Mizuno T.;Fei L.;Wong H.R.;Vinks A.A. 11-01-2018. Phase 1 safety and pharmacokinetic study on the use of pioglitazone in critically ill patients with Intensive Care Medicine, 44 11, 2006-2008Alloway R.R.;Vinks A.A.;Fukuda T.;Mizuno T.;King E.C.;Zou Y.;Jiang W.;Woodle E.S.;Tremblay S.;Klawitter J.;Klawitter J.;Christians U. 11-01-2017. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A PLoS Medicine, 14 11, Shinsako K.;Mizuno T.;Terada T.;Watanabe J.;Kamba T.;Nakamura E.;Ogawa O.;Inui K.I. 10-01-2010. Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: A case study International Journal of Clinical Oncology, 15 5, 512-514Dong M.;Mizuno T.;Vinks A. 09-01-2017. Opportunities for model-based precision dosing in the treatment of sickle cell anemia Blood Cells, Molecules, and Diseases, 67 , 143-147Togashi Y.;Masago K.;Masuda S.;Mizuno T.;Fukudo M.;Ikemi Y.;Sakamori Y.;Nagai H.;Kim Y.;Katsura T.;Mishima M. 09-01-2012. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung ca Cancer Chemotherapy and Pharmacology, 70 3, 399-405Hahn D.;Fukuda T.;Euteneuer J.C.;Mizuno T.;Vinks A.A.;Sadhasivam S.;Emoto C. 08-01-2020. Influence of MRP3 Genetics and Hepatic Expression Ontogeny for Morphine Disposition in Neonatal and Journal of Clinical Pharmacology, 60 8, 992-998McGann P.T.;Niss O.;Dong M.;Marahatta A.;Howard T.A.;Mizuno T.;Lane A.;Kalfa T.A.;Malik P.;Quinn C.T.;Ware R.E.;Vinks A.A. 08-01-2019. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for y American Journal of Hematology, 94 8, 871-879Mizuno T.;Fukuda T.;Emoto C.;Mobberley-Schuman P.;Hammill A.;Adams D.;Vinks A. 08-01-2017. Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infan Pediatric Blood and Cancer, 64 8, Emoto C.;Fukuda T.;Mizuno T.;Schniedewind B.;Christians U.;Adams D.;Vinks A. 08-01-2016. Characterizing the developmental trajectory of sirolimus clearance in neonates and infants CPT: Pharmacometrics and Systems Pharmacology, 5 8, 411-417Kunimatsu S.;Mizuno T.;Fukudo M.;Katsura T. 08-01-2013. Effect of P-glycoprotein and breast cancer resistance protein inhibition on the pharmacokinetics of Drug Metabolism and Disposition, 41 8, 1592-1597Dong M.;McGann P.;Mizuno T.;Ware R.;Vinks A. 07-01-2018. Model-based dosing with concentration feedback as an integral part of personalized hydroxycarbamide British Journal of Clinical Pharmacology, 84 7, 1410-1412Faircloth J.M.;Miner K.M.;Alsaied T.;Nelson N.;Ciambarella J.;Mizuno T.;Palumbo J.S.;Vinks A.A.;Veldtman G.R. 07-01-2017. Time in therapeutic range as a marker for thrombotic and bleeding outcomes in Fontan patients Journal of Thrombosis and Thrombolysis, 44 1, 38-47Brunet M.;Van Gelder T.;Åsberg A.;Haufroid V.;Hesselink D.;Langman L.;Lemaitre F.;Marquet P.;Seger C.;Shipkova M.;Vinks A.;Wallemacq P.;Wieland E.;Woillard J.;Barten M.;Budde K.;Colom H.;Dieterlen M.;Elens L.;Johnson-Davis K.;Kunicki P.;Macphee I.;Masuda S.;Mathew B.;Millán O.;Mizuno T.;Moes D.;Monchaud C.;Noceti O.;Pawinski T.;Picard N.;Van Schaik R.;Sommerer C.;Vethe N.;De Winter B.;Christians U.;Bergan S. 06-01-2019. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report Therapeutic Drug Monitoring, 41 3, 261-307Mizuno T.;Gist K.M.;Gao Z.;Wempe M.F.;Alten J.;Cooper D.S.;Goldstein S.L.;Vinks A.A. 06-01-2019. Developmental Pharmacokinetics and Age-Appropriate Dosing Design of Milrinone in Neonates and Infant Clinical Pharmacokinetics, 58 6, 793-803Diwan T.;Lichvar A.;Leino A.;Vinks A.;Christians U.;Shields A.;Cardi M.;Fukuda T.;Mizuno T.;Kaiser T.;Woodle E.;Alloway R. 06-01-2017. Pharmacokinetic and pharmacogenetic analysis of immunosuppressive agents after laparoscopic sleeve g Clinical Transplantation, 31 6, Tsuda M.;Terada T.;Mizuno T.;Katsura T.;Shimakura J.;Inui K. 06-01-2009. Targeted disruption of the multidrug and toxin extrusion 1 (Mate1) gene in mice reduces renal secret Molecular Pharmacology, 75 6, 1280-1286van Hoogdalem M.W.;Emoto C.;Fukuda T.;Mizuno T.;Mehta P.A.;Vinks A.A. 05-01-2020. Population pharmacokinetic modelling of busulfan and the influence of body composition in paediatric British Journal of Clinical Pharmacology, 86 5, 933-943Ramsey L.;Mizuno T.;Vinks A.;O'Brien M. 05-01-2019. Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving Pediatric Blood and Cancer, 66 5, Balyan R.;Zhang X.;Chidambaran V.;Martin L.;Mizuno T.;Fukuda T.;Vinks A.;Sadhasivam S. 05-01-2017. OCT1 genetic variants are associated with postoperative morphine-related adverse effects in children Pharmacogenomics, 18 7, 621-629Gist K.;Cooper D.;Wrona J.;Faubel S.;Altmann C.;Gao Z.;Marino B.;Alten J.;Hock K.;Mizuno T.;Vinks A.;Joy M.;Wempe M.;Bennett M.;Goldstein S. 04-01-2018. Acute Kidney Injury Biomarkers Predict an Increase in Serum Milrinone Concentration Earlier Than Ser Therapeutic Drug Monitoring, 40 2, 186-194Dong M.;McGann P.;Mizuno T.;Ware R.;Vinks A. 04-01-2016. Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in British Journal of Clinical Pharmacology, 81 4, 742-752Hahn A.;Fukuda T.;Hahn D.;Mizuno T.;Frenck R.;Vinks A. 04-01-2016. Pharmacokinetics and pharmacogenomics of ?-lactam-induced neutropenia Pharmacogenomics, 17 6, 547-559Mizuno T.;Mohri K.;Nasu S.;Danjo K.;Okamoto H. 03-04-2009. Dual imaging of pulmonary delivery and gene expression of dry powder inhalant by fluorescence and bi Journal of Controlled Release, 134 2, 149-154Hahn D.;Emoto C.;Euteneuer J.;Mizuno T.;Vinks A.;Fukuda T. 03-01-2019. Influence of OCT1 Ontogeny and Genetic Variation on Morphine Disposition in Critically Ill Neonates: Clinical Pharmacology and Therapeutics, 105 3, 761-768Chidambaran V.;Venkatasubramanian R.;Zhang X.;Martin L.;Niu J.;Mizuno T.;Fukuda T.;Meller J.;Vinks A.;Sadhasivam S. 03-01-2017. ABCC3 genetic variants are associated with postoperative morphine-induced respiratory depression and Pharmacogenomics Journal, 17 2, 162-169Ramsey L.;Mizuno T.;Vinks A.;Margolis P. 03-01-2017. Learning Health Systems as Facilitators of Precision Medicine Clinical Pharmacology and Therapeutics, 101 3, 359-367Nehus E.;Mizuno T.;Cox S.;Goldstein S.;Vinks A. 03-01-2016. Pharmacokinetics of meropenem in children receiving continuous renal replacement therapy: Validation Journal of clinical pharmacology, 56 3, 291-297Kodawara T.;Mizuno T.;Taue H.;Hashida T.;Yano I.;Katsura T.;Inui K. 03-01-2009. Evaluation of stability of temozolomide in solutions after opening the capsule Yakugaku Zasshi, 129 3, 353-357Bauman L.E.;Xiong Y.;Mizuno T.;Minar P.;Fukuda T.;Dong M.;Rosen M.J.;Vinks A.A. 02-11-2020. Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Diseases, 26 3, 429-439Mizuno T.;Terada T.;Kamba T.;Fukudo M.;Katsura T.;Nakamura E.;Ogawa O.;Inui K. 02-06-2010. ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcino Annals of Oncology, 21 6, 1382-1383Emoto C.;Hahn D.;Euteneuer J.;Mizuno T.;Vinks A.;Fukuda T. 02-01-2020. Next Challenge From the Variance in Individual Physiologically-Based Pharmacokinetic Model-Predicted Clinical Pharmacology and Therapeutics, 107 2, 319-320Mizuno T.;O'Brien M.;Vinks A. 02-01-2019. Significant effect of infection and food intake on sirolimus pharmacokinetics and exposure in pediat European Journal of Pharmaceutical Sciences, 128 , 209-214Fukudo M.;Ito T.;Mizuno T.;Shinsako K.;Hatano E.;Uemoto S.;Kamba T.;Yamasaki T.;Ogawa O.;Seno H.;Chiba T.;Matsubara K. 02-01-2014. Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepat Clinical Pharmacokinetics, 53 2, 185-196Mizuno T.;Dong M.;Taylor Z.L.;Ramsey L.B.;Vinks A.A. 01-01-2020. Clinical implementation of pharmacogenetics and model-informed precision dosing to improve patient c British Journal of Clinical Pharmacology, , Tang Girdwood S.C.;Mizuno T.;Krallman K.A.;Benken L.A.;Stoneman E.M.;Yunger T.M.;Wong H.R.;Vinks A.A.;Kaplan J.M. 01-01-2020. Route of oseltamivir administration affects metabolite concentrations in critically ill children Pediatric Infectious Disease Journal, , 1224-1227Taylor Z.L.;Mizuno T.;Punt N.C.;Baskaran B.;Navarro Sainz A.;Shuman W.;Felicelli N.;Vinks A.A.;Heldrup J.;Ramsey L.B. 01-01-2020. MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to In Clinical Pharmacology and Therapeutics, , Vinks A.A.;Punt N.C.;Menke F.;Kirkendall E.;Butler D.;Duggan T.J.;Cortezzo D.M.E.;Kiger S.;Dietrich T.;Spencer P.;Keefer R.;Setchell K.D.R.;Zhao J.;Euteneuer J.C.;Mizuno T.;Dufendach K.R. 01-01-2020. Electronic Health Record–Embedded Decision Support Platform for Morphine Precision Dosing in Neonate Clinical Pharmacology and Therapeutics, 107 1, 186-194Boucher A.;Mizuno T.;Vinks A.;Goldstein S.;Tiao G.;Geller J. 01-01-2019. Dose modifications and pharmacokinetics of adjuvant cisplatin monotherapy while on hemodialysis for Pediatric Blood and Cancer, 66 1, Cabrera-Salcedo C.;Mizuno T.;Tyzinski L.;Andrew M.;Vinks A.A.;Frystyk J.;Wasserman H.;Gordon C.M.;Hwa V.;Backeljauw P.;Dauber A. 01-01-2017. Pharmacokinetics of IGF-1 in PAPP-A2-deficient patients, growth response, and effects on glucose and Journal of Clinical Endocrinology and Metabolism, 102 12, 4568-4577Chidambaran V.;Pilipenko V.;Spruance K.;Venkatasubramanian R.;Niu J.;Fukuda T.;Mizuno T.;Zhang K.;Kaufman K.;Vinks A.;Martin L.;Sadhasivam S. 01-01-2017. Fatty acid amide hydrolase-morphine interaction influences ventilatory response to hypercapnia and p Pharmacogenomics, 18 2, 143-156Mizuno T.;Fukuda T.;Christians U.;Perentesis J.;Fouladi M.;Vinks A. 01-01-2017. Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: British Journal of Clinical Pharmacology, 83 5, 1097-1107Emoto C.;Fukuda T.;Mizuno T.;Cox S.;Schniedewind B.;Christians U.;Widemann B.C.;Fisher M.J.;Weiss B.;Perentesis J.;Vinks A.A. 01-01-2015. Age-dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1 Therapeutic Drug Monitoring, 37 3, 395-399Gist K.M.;Mizuno T.;Goldstein S.L.;Vinks A. 01-01-2015. Retrospective evaluation of milrinone pharmacokinetics in children with kidney injury Therapeutic Drug Monitoring, 37 6, 792-796Ishii T.;Hatano E.;Taura K.;Mizuno T.;Kawai T.;Fukudo M.;Katsura T.;Uemoto S. 01-01-2014. Sorafenib in a hepatocellular carcinoma patient with end-stage renal failure: A pharmacokinetic stud Hepatology Research, 44 6, 685-688Mizuno T.;Fukuda T.;Masuda S.;Uemoto S.;Matsubara K.;Inui K.;Vinks A. 01-01-2014. Developmental trajectory of intestinal MDR1/ABCB1 mRNA expression in children British Journal of Clinical Pharmacology, 77 5, 910-912Mizuno T.;Fukudo M.;Fukuda T.;Terada T.;Dong M.;Kamba T.;Yamasaki T.;Ogawa O.;Katsura T.;Inui K.I.;Vinks A.A.;Matsubara K. 01-01-2014. The Effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal Therapeutic Drug Monitoring, 36 3, 310-316Venkatasubramanian R.;Fukuda T.;Niu J.;Mizuno T.;Chidambaran V.;Vinks A.;Sadhasivam S. 01-01-2014. ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children Pharmacogenomics, 15 10, 1297-1309Fukuda T.;Chidambaran V.;Mizuno T.;Venkatasubramanian R.;Ngamprasertwong P.;Olbrecht V.;Esslinger H.;Vinks A.;Sadhasivam S. 01-01-2013. OCT1 genetic variants influence the pharmacokinetics of morphine in children Pharmacogenomics, 14 10, 1141-1151Mizuno T.;Fukudo M.;Terada T.;Kamba T.;Nakamura E.;Ogawa O.;Inui K.I.;Katsura T. 01-01-2012. Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacoki Drug Metabolism and Pharmacokinetics, 27 6, 631-639
Wiles J.;Isemann B.;Mizuno T.;Tabangin M.;Ward L.;Akinbi H.;Vinks A. 12-01-2015. Pharmacokinetics of Oral Methadone in the Treatment of Neonatal Abstinence Syndrome: A Pilot Study The Journal of pediatrics, 167 6, 1214-1220.e3Mizuno T.;Emoto C.;Fukuda T.;Hammill A.;Adams D.;Vinks A. 11-15-2017. Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies European Journal of Pharmaceutical Sciences, 109 , S124-S131Kaplan J.M.;Zingarelli B.;Krallman K.;Tang Girdwood S.;Lagory D.;Mizuno T.;Fei L.;Wong H.R.;Vinks A.A. 11-01-2018. Phase 1 safety and pharmacokinetic study on the use of pioglitazone in critically ill patients with Intensive Care Medicine, 44 11, 2006-2008Alloway R.R.;Vinks A.A.;Fukuda T.;Mizuno T.;King E.C.;Zou Y.;Jiang W.;Woodle E.S.;Tremblay S.;Klawitter J.;Klawitter J.;Christians U. 11-01-2017. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A PLoS Medicine, 14 11, Shinsako K.;Mizuno T.;Terada T.;Watanabe J.;Kamba T.;Nakamura E.;Ogawa O.;Inui K.I. 10-01-2010. Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: A case study International Journal of Clinical Oncology, 15 5, 512-514Dong M.;Mizuno T.;Vinks A. 09-01-2017. Opportunities for model-based precision dosing in the treatment of sickle cell anemia Blood Cells, Molecules, and Diseases, 67 , 143-147Togashi Y.;Masago K.;Masuda S.;Mizuno T.;Fukudo M.;Ikemi Y.;Sakamori Y.;Nagai H.;Kim Y.;Katsura T.;Mishima M. 09-01-2012. Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung ca Cancer Chemotherapy and Pharmacology, 70 3, 399-405Hahn D.;Fukuda T.;Euteneuer J.C.;Mizuno T.;Vinks A.A.;Sadhasivam S.;Emoto C. 08-01-2020. Influence of MRP3 Genetics and Hepatic Expression Ontogeny for Morphine Disposition in Neonatal and Journal of Clinical Pharmacology, 60 8, 992-998McGann P.T.;Niss O.;Dong M.;Marahatta A.;Howard T.A.;Mizuno T.;Lane A.;Kalfa T.A.;Malik P.;Quinn C.T.;Ware R.E.;Vinks A.A. 08-01-2019. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for y American Journal of Hematology, 94 8, 871-879Mizuno T.;Fukuda T.;Emoto C.;Mobberley-Schuman P.;Hammill A.;Adams D.;Vinks A. 08-01-2017. Developmental pharmacokinetics of sirolimus: Implications for precision dosing in neonates and infan Pediatric Blood and Cancer, 64 8, Emoto C.;Fukuda T.;Mizuno T.;Schniedewind B.;Christians U.;Adams D.;Vinks A. 08-01-2016. Characterizing the developmental trajectory of sirolimus clearance in neonates and infants CPT: Pharmacometrics and Systems Pharmacology, 5 8, 411-417Kunimatsu S.;Mizuno T.;Fukudo M.;Katsura T. 08-01-2013. Effect of P-glycoprotein and breast cancer resistance protein inhibition on the pharmacokinetics of Drug Metabolism and Disposition, 41 8, 1592-1597Dong M.;McGann P.;Mizuno T.;Ware R.;Vinks A. 07-01-2018. Model-based dosing with concentration feedback as an integral part of personalized hydroxycarbamide British Journal of Clinical Pharmacology, 84 7, 1410-1412Faircloth J.M.;Miner K.M.;Alsaied T.;Nelson N.;Ciambarella J.;Mizuno T.;Palumbo J.S.;Vinks A.A.;Veldtman G.R. 07-01-2017. Time in therapeutic range as a marker for thrombotic and bleeding outcomes in Fontan patients Journal of Thrombosis and Thrombolysis, 44 1, 38-47Brunet M.;Van Gelder T.;Åsberg A.;Haufroid V.;Hesselink D.;Langman L.;Lemaitre F.;Marquet P.;Seger C.;Shipkova M.;Vinks A.;Wallemacq P.;Wieland E.;Woillard J.;Barten M.;Budde K.;Colom H.;Dieterlen M.;Elens L.;Johnson-Davis K.;Kunicki P.;Macphee I.;Masuda S.;Mathew B.;Millán O.;Mizuno T.;Moes D.;Monchaud C.;Noceti O.;Pawinski T.;Picard N.;Van Schaik R.;Sommerer C.;Vethe N.;De Winter B.;Christians U.;Bergan S. 06-01-2019. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report Therapeutic Drug Monitoring, 41 3, 261-307Mizuno T.;Gist K.M.;Gao Z.;Wempe M.F.;Alten J.;Cooper D.S.;Goldstein S.L.;Vinks A.A. 06-01-2019. Developmental Pharmacokinetics and Age-Appropriate Dosing Design of Milrinone in Neonates and Infant Clinical Pharmacokinetics, 58 6, 793-803Diwan T.;Lichvar A.;Leino A.;Vinks A.;Christians U.;Shields A.;Cardi M.;Fukuda T.;Mizuno T.;Kaiser T.;Woodle E.;Alloway R. 06-01-2017. Pharmacokinetic and pharmacogenetic analysis of immunosuppressive agents after laparoscopic sleeve g Clinical Transplantation, 31 6, Tsuda M.;Terada T.;Mizuno T.;Katsura T.;Shimakura J.;Inui K. 06-01-2009. Targeted disruption of the multidrug and toxin extrusion 1 (Mate1) gene in mice reduces renal secret Molecular Pharmacology, 75 6, 1280-1286van Hoogdalem M.W.;Emoto C.;Fukuda T.;Mizuno T.;Mehta P.A.;Vinks A.A. 05-01-2020. Population pharmacokinetic modelling of busulfan and the influence of body composition in paediatric British Journal of Clinical Pharmacology, 86 5, 933-943Ramsey L.;Mizuno T.;Vinks A.;O'Brien M. 05-01-2019. Delayed methotrexate clearance in patients with acute lymphoblastic leukemia concurrently receiving Pediatric Blood and Cancer, 66 5, Balyan R.;Zhang X.;Chidambaran V.;Martin L.;Mizuno T.;Fukuda T.;Vinks A.;Sadhasivam S. 05-01-2017. OCT1 genetic variants are associated with postoperative morphine-related adverse effects in children Pharmacogenomics, 18 7, 621-629Gist K.;Cooper D.;Wrona J.;Faubel S.;Altmann C.;Gao Z.;Marino B.;Alten J.;Hock K.;Mizuno T.;Vinks A.;Joy M.;Wempe M.;Bennett M.;Goldstein S. 04-01-2018. Acute Kidney Injury Biomarkers Predict an Increase in Serum Milrinone Concentration Earlier Than Ser Therapeutic Drug Monitoring, 40 2, 186-194Dong M.;McGann P.;Mizuno T.;Ware R.;Vinks A. 04-01-2016. Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in British Journal of Clinical Pharmacology, 81 4, 742-752Hahn A.;Fukuda T.;Hahn D.;Mizuno T.;Frenck R.;Vinks A. 04-01-2016. Pharmacokinetics and pharmacogenomics of ?-lactam-induced neutropenia Pharmacogenomics, 17 6, 547-559Mizuno T.;Mohri K.;Nasu S.;Danjo K.;Okamoto H. 03-04-2009. Dual imaging of pulmonary delivery and gene expression of dry powder inhalant by fluorescence and bi Journal of Controlled Release, 134 2, 149-154Hahn D.;Emoto C.;Euteneuer J.;Mizuno T.;Vinks A.;Fukuda T. 03-01-2019. Influence of OCT1 Ontogeny and Genetic Variation on Morphine Disposition in Critically Ill Neonates: Clinical Pharmacology and Therapeutics, 105 3, 761-768Chidambaran V.;Venkatasubramanian R.;Zhang X.;Martin L.;Niu J.;Mizuno T.;Fukuda T.;Meller J.;Vinks A.;Sadhasivam S. 03-01-2017. ABCC3 genetic variants are associated with postoperative morphine-induced respiratory depression and Pharmacogenomics Journal, 17 2, 162-169Ramsey L.;Mizuno T.;Vinks A.;Margolis P. 03-01-2017. Learning Health Systems as Facilitators of Precision Medicine Clinical Pharmacology and Therapeutics, 101 3, 359-367Nehus E.;Mizuno T.;Cox S.;Goldstein S.;Vinks A. 03-01-2016. Pharmacokinetics of meropenem in children receiving continuous renal replacement therapy: Validation Journal of clinical pharmacology, 56 3, 291-297Kodawara T.;Mizuno T.;Taue H.;Hashida T.;Yano I.;Katsura T.;Inui K. 03-01-2009. Evaluation of stability of temozolomide in solutions after opening the capsule Yakugaku Zasshi, 129 3, 353-357Bauman L.E.;Xiong Y.;Mizuno T.;Minar P.;Fukuda T.;Dong M.;Rosen M.J.;Vinks A.A. 02-11-2020. Improved Population Pharmacokinetic Model for Predicting Optimized Infliximab Exposure in Pediatric Inflammatory Bowel Diseases, 26 3, 429-439Mizuno T.;Terada T.;Kamba T.;Fukudo M.;Katsura T.;Nakamura E.;Ogawa O.;Inui K. 02-06-2010. ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcino Annals of Oncology, 21 6, 1382-1383Emoto C.;Hahn D.;Euteneuer J.;Mizuno T.;Vinks A.;Fukuda T. 02-01-2020. Next Challenge From the Variance in Individual Physiologically-Based Pharmacokinetic Model-Predicted Clinical Pharmacology and Therapeutics, 107 2, 319-320Mizuno T.;O'Brien M.;Vinks A. 02-01-2019. Significant effect of infection and food intake on sirolimus pharmacokinetics and exposure in pediat European Journal of Pharmaceutical Sciences, 128 , 209-214Fukudo M.;Ito T.;Mizuno T.;Shinsako K.;Hatano E.;Uemoto S.;Kamba T.;Yamasaki T.;Ogawa O.;Seno H.;Chiba T.;Matsubara K. 02-01-2014. Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepat Clinical Pharmacokinetics, 53 2, 185-196Mizuno T.;Dong M.;Taylor Z.L.;Ramsey L.B.;Vinks A.A. 01-01-2020. Clinical implementation of pharmacogenetics and model-informed precision dosing to improve patient c British Journal of Clinical Pharmacology, , Tang Girdwood S.C.;Mizuno T.;Krallman K.A.;Benken L.A.;Stoneman E.M.;Yunger T.M.;Wong H.R.;Vinks A.A.;Kaplan J.M. 01-01-2020. Route of oseltamivir administration affects metabolite concentrations in critically ill children Pediatric Infectious Disease Journal, , 1224-1227Taylor Z.L.;Mizuno T.;Punt N.C.;Baskaran B.;Navarro Sainz A.;Shuman W.;Felicelli N.;Vinks A.A.;Heldrup J.;Ramsey L.B. 01-01-2020. MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to In Clinical Pharmacology and Therapeutics, , Vinks A.A.;Punt N.C.;Menke F.;Kirkendall E.;Butler D.;Duggan T.J.;Cortezzo D.M.E.;Kiger S.;Dietrich T.;Spencer P.;Keefer R.;Setchell K.D.R.;Zhao J.;Euteneuer J.C.;Mizuno T.;Dufendach K.R. 01-01-2020. Electronic Health Record–Embedded Decision Support Platform for Morphine Precision Dosing in Neonate Clinical Pharmacology and Therapeutics, 107 1, 186-194Boucher A.;Mizuno T.;Vinks A.;Goldstein S.;Tiao G.;Geller J. 01-01-2019. Dose modifications and pharmacokinetics of adjuvant cisplatin monotherapy while on hemodialysis for Pediatric Blood and Cancer, 66 1, Cabrera-Salcedo C.;Mizuno T.;Tyzinski L.;Andrew M.;Vinks A.A.;Frystyk J.;Wasserman H.;Gordon C.M.;Hwa V.;Backeljauw P.;Dauber A. 01-01-2017. Pharmacokinetics of IGF-1 in PAPP-A2-deficient patients, growth response, and effects on glucose and Journal of Clinical Endocrinology and Metabolism, 102 12, 4568-4577Chidambaran V.;Pilipenko V.;Spruance K.;Venkatasubramanian R.;Niu J.;Fukuda T.;Mizuno T.;Zhang K.;Kaufman K.;Vinks A.;Martin L.;Sadhasivam S. 01-01-2017. Fatty acid amide hydrolase-morphine interaction influences ventilatory response to hypercapnia and p Pharmacogenomics, 18 2, 143-156Mizuno T.;Fukuda T.;Christians U.;Perentesis J.;Fouladi M.;Vinks A. 01-01-2017. Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: British Journal of Clinical Pharmacology, 83 5, 1097-1107Emoto C.;Fukuda T.;Mizuno T.;Cox S.;Schniedewind B.;Christians U.;Widemann B.C.;Fisher M.J.;Weiss B.;Perentesis J.;Vinks A.A. 01-01-2015. Age-dependent changes in sirolimus metabolite formation in patients with neurofibromatosis type 1 Therapeutic Drug Monitoring, 37 3, 395-399Gist K.M.;Mizuno T.;Goldstein S.L.;Vinks A. 01-01-2015. Retrospective evaluation of milrinone pharmacokinetics in children with kidney injury Therapeutic Drug Monitoring, 37 6, 792-796Ishii T.;Hatano E.;Taura K.;Mizuno T.;Kawai T.;Fukudo M.;Katsura T.;Uemoto S. 01-01-2014. Sorafenib in a hepatocellular carcinoma patient with end-stage renal failure: A pharmacokinetic stud Hepatology Research, 44 6, 685-688Mizuno T.;Fukuda T.;Masuda S.;Uemoto S.;Matsubara K.;Inui K.;Vinks A. 01-01-2014. Developmental trajectory of intestinal MDR1/ABCB1 mRNA expression in children British Journal of Clinical Pharmacology, 77 5, 910-912Mizuno T.;Fukudo M.;Fukuda T.;Terada T.;Dong M.;Kamba T.;Yamasaki T.;Ogawa O.;Katsura T.;Inui K.I.;Vinks A.A.;Matsubara K. 01-01-2014. The Effect of ABCG2 genotype on the population pharmacokinetics of sunitinib in patients with renal Therapeutic Drug Monitoring, 36 3, 310-316Venkatasubramanian R.;Fukuda T.;Niu J.;Mizuno T.;Chidambaran V.;Vinks A.;Sadhasivam S. 01-01-2014. ABCC3 and OCT1 genotypes influence pharmacokinetics of morphine in children Pharmacogenomics, 15 10, 1297-1309Fukuda T.;Chidambaran V.;Mizuno T.;Venkatasubramanian R.;Ngamprasertwong P.;Olbrecht V.;Esslinger H.;Vinks A.;Sadhasivam S. 01-01-2013. OCT1 genetic variants influence the pharmacokinetics of morphine in children Pharmacogenomics, 14 10, 1141-1151Mizuno T.;Fukudo M.;Terada T.;Kamba T.;Nakamura E.;Ogawa O.;Inui K.I.;Katsura T. 01-01-2012. Impact of genetic variation in breast cancer resistance protein (BCRP/ABCG2) on sunitinib pharmacoki Drug Metabolism and Pharmacokinetics, 27 6, 631-639